Pemetrexed+carboplatin

DRUG3 trials

Sponsors

AstraZeneca, Dizal Pharmaceuticals, Sichuan University

Conditions

Malignant TumorsNon-small Cell Lung CancerNon-small Cell Lung Cancer NSCLC

Phase 1

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

RecruitingNCT07004244

Sichuan UniversityMalignant Tumors

Start: 2025-06-05End: 2027-12-31Target: 20Updated: 2025-06-24

Phase 2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active, not recruitingNCT03775486

AstraZenecaNon-small Cell Lung Cancer NSCLC

Start: 2018-12-21End: 2026-09-27Updated: 2026-02-10

Phase 3

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Active, not recruitingNCT05668988

Dizal PharmaceuticalsNon-small Cell Lung Cancer

Start: 2022-12-13End: 2027-10-31Updated: 2026-02-17

Related Papers

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial

Journal of Clinical Oncology2025-01-2916 citations

Mobocertinib: Mechanism of action, clinical, and translational science

Clinical and Translational Science2024-03-0116 citations

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.

2023-12-1254 citations

Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.

2023-06-298 citations

Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations.

Journal of Clinical Oncology2023-06-0114 citations

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.

2022-08-1136 citations

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2019-05-204 citations